The common adiponutrin variant p.I148m does not confer gallstone risk but affects fasting glucose and triglyceride levels

Journal of Physiology and Pharmacology

Volumn 62, Issue 3, 2011, Pages 369-375

  Krawczyk, M ^a   Gruenhage, F ^a   Mahler, M ^a   Tirziu, S ^b   Acalovschi, M ^b   Lammert, F ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Adiponutrin; Insulin resistance; Metabolic syndrome; PNPLA3; Single nucleotide polymorphism; Triglyceride

Indexed keywords

5' NUCLEASE; ADIPONUTRIN; CHOLESTEROL; GLUCOSE; LIVER ENZYME; NUCLEASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GALLSTONE; GENE; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PNPLA3 GENE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CHOLESTEROL; FATTY LIVER; FEMALE; GALLSTONES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIVER DISEASES, ALCOHOLIC; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SIBLINGS; TRIGLYCERIDES; YOUNG ADULT;

EID: 80355123774     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Lammert F, Miquel JF. Gallstone disease: from genes to evidence-based therapy. J Hepatol 2008; 48(Suppl 1): S124-135.
2. Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology 2005; 41: 1138-1143.
3. Buch S, Schafmayer C, Volzke H, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet 2007; 39: 995-999.
4. Gruenhage F, Acalovschi M, Tirziu S, et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology 2007; 46: 793-801.
5. Katsika D, Magnusson P, Krawczyk M, et al. Gallstone disease in Swedish twins: risk is associated with ABCG8 D19H genotype. J Intern Med 2010; 268: 279-285.
6. Kovacs P, Kress R, Rocha J, et al. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans. J Hepatol 2008; 48: 116-124.
7. Renner O, Harsch S, Schaeffeler E, et al. A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease. PLoS One 2009; 4: e7321.
8. Buch S, Schafmayer C, Volzke H, et al. Loci from a genomewide analysis of bilirubin levels are associated with gallstone risk and composition. Gastroenterology 2010; 139: 1942-1951.
9. Krawczyk M, Rusticeanu M, Grunhage F, et al. Analysis of the common vasoactive intestinal peptide receptor 1 polymorphism in gallstone patients. J Gastrointestin Liver Dis 2010; 19: 273-277.
10. Acalovschi M, Tirziu S, Chiorean E, Krawczyk M, Gruenhage F, Lammert F. Common variants of ABCB4 and ABCB11 and plasma lipid levels: a study in sib pairs with gallstones, and controls. Lipids 2009; 44: 521-526.
11. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet 2006; 368: 230-239.
12. Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008; 14: 778-782.
13. Ruhl CE, Everhart JE. Association of diabetes, serum insulin, and C-peptide with gallbladder disease. Hepatology 2000; 31: 299-303.
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
15. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. IDF Epidemiology Task Force Consensus Group. Lancet 2005; 366: 1059-1062.
16. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24: 695-708.
17. Duvnjak M, Tomasic V, Gomercic M, et al. Therapy of nonalcoholic fatty liver disease: current status. J Physiol Pharmacol 2009; 60(Suppl 7): 57-66.
18. Palasciano G, Moschetta A, Palmieri VO, Grattagliano I, Iacobellis G, Portincasa P. Non-alcoholic fatty liver disease in the metabolic syndrome. Curr Pharm Des 2007; 13: 2193-2198.
19. Portincasa P, Wallner G, Krawczyk M, Ciechanski A, Maciejwski R. Current opinions of pathophysiology, diagnosis and treatment of nonalcoholic steatohepatitis. Gastroenterologia Polska 2006; 16: 501-506.
20. Loria P, Lonardo A, Lombardini S, et al. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol 2005; 20: 1176-1184.
21. Krawczyk K, Szczesniak P, Kumor A, et al. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH). J Physiol Pharmacol 2009; 60(Suppl 3): 71-75.
22. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465.
23. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2009; 42: 21-23.
24. Stickel F, Buch S, Lau K, et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011; 53: 86-95.
25. Trepo E, Gustot T, Degre D, et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol (in press), doi:10.1016/j.jhep.2011.01.028.
26. Corradini SG, Burza MA, Molinaro A, Romeo S. Patatin-like phospholipase domain containing 3 sequence variant and hepatocellular carcinoma. Hepatology 2011; 53: 1776.
27. Valenti L, Colombo M, Fargion S. PNPLA3 genotype and hepatocellular carcinoma in chronic hepatitis C. Hepatology (in press), doi: 10.1002/hep.24265.
28. Johansson LE, Lindblad U, Larsson CA, Rastam L, Ridderstrale M. Polymorphisms in the adiponutrin gene are associated with increased insulin secretion and obesity. Eur J Endocrinol 2008; 159: 577-583.
29. Kantartzis K, Peter A, Machicao F, et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 2009; 58: 2616-2623.
30. He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-6715.
31. Krawczyk M, Gruenhage F, Zimmer V, Lammert F. Variant adiponutrin (PNPLA3) represents a common fibrosis risk gene: non-invasive elastography-based study in chronic liver disease. J Hepatol 2011; 55: 299-306.
32. Acalovschi M, Badea R, Dumitrascu D, Varga C. Prevalence of gallstones in liver cirrhosis: a sonographic survey. Am J Gastroenterol 1988; 83: 954-956.
33. Del Olmo JA, Garcia F, Serra MA, Maldonado L, Rodrigo JM. Prevalence and incidence of gallstones in liver cirrhosis. Scand J Gastroenterol 1997; 32: 1061-1065.
34. Acalovschi M, Ciocan A, Mostean O, et al. Are plasma lipid levels related to ABCG5/ABCG8 polymorphisms? A preliminary study in siblings with gallstones. Eur J Intern Med 2006; 17: 490-494.
35. Krawczyk M, Mihalache F, Hoblinger A, Acalovschi M, Lammert F, Zimmer V. The pancreatic cancer risk variant ABO rs505922 in patients with cholangiocarcinoma. World J Gastroenterol 2011; (in press).
36. Dietter J, Mattheisen M, Furst R, Ruschendorf F, Wienker TF, Strauch K. Linkage analysis using sex-specific recombination fractions with GENEHUNTERMODSCORE. Bioinformatics 2007; 23: 64-70.
37. Krysiak R, Okopien B. Different effects of simvastatin on ex vivo monocyte cytokine release in patients with hypercholesterolemia and impaired glucose tolerance. J Physiol Pharmacol 2010; 61: 725-732.
38. Bodmer M, Brauchli YB, Krahenbuhl S, Jick SS, Meier CR. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA 2009; 302: 2001-2007.
39. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Statin use and the risk of cholecystectomy in women. Gastroenterology 2009; 136: 1593-1600.
40. Kotronen A, Johansson LE, Johansson LM, et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009; 52: 1056-1060.
41. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209-1217.
42. Speliotes EK, Butler JL, Palmer CD, et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 2010; 52: 904-912.
43. Speliotes EK, Yerges-Armstrong LM, Wu J, et al. Genomewide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011; 7: e1001324.
44. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894.
45. Kollerits B, Coassin S, Beckmann ND, et al. Genetic evidence for a role of adiponutrin in the metabolism of apolipoprotein B-containing lipoproteins. Hum Mol Genet 2009; 18: 4669-4676.